Covaxin Trial
- All
- News
- Videos
-
US Health Regulator Lifts Hold On Covaxin's Clinical Trials
The US Food and Drug Administration which has put on hold phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for jab in US, Canada
-
US Health Regulator Clears Covaxin For Clinical Trials In Adults In America
Bharat Biotech's COVID-19 vaccine Covaxin has been given clearance for clinical trials in adults by the US Food and Drug Administration (FDA).
-
Covaxin Maker Bharat Biotech's Nasal Booster Dose Trials Get Approval
Vaccine manufacturer Bharat Biotech has received approval to conduct Phase-III clinical trials of an intranasal booster dose on people who have received both doses of Covaxin.
-
Covaxin-Maker Says Booster Shot Over 90% Effective Against Omicron, Delta Variant
Bharat Biotech today said that trials have indicated that a booster shot of Covaxin neutralises the Delta and Omicron variants of Covid.
-
Data From Trials On 2-18-Year-Olds Very Encouraging: Covaxin Maker
Bharat Biotech today announced that Covaxin, its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III trials.
-
Covaxin Showed Good Response In Children During Trials: Covid Panel Chief
Covaxin has shown that it has a very good immune response in children in trials, Chairman of India's COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI) Dr NK Arora said on Sunday.
-
Centre's Decision To Vaccinate Children "Unscientific": Senior AIIMS Epidemiologist
A senior epidemiologist at AIIMS who is the principal investigator of Covaxin trials for adults and children at the institute on Sunday termed the Centre's decision to vaccinate children against Covid "unscientific".
-
Covaxin Meets WHO Criteria For Delta, Shows Lancet Study: Bharat Biotech
Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among the general population.
-
Bharat Biotech's US Partner Files Request With FDA For Covaxin Trials
Ocugen, Bharat Biotech's US partner for COVID-19 vaccine Covaxin, on Wednesday said it has submitted Investigational New Drug Application (IND) to the US Food and Drug Administration to conduct clinical trials.
-
Paediatric Covaxin: Bharat Biotech Completes Phase 2/3 Trials
Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman and Managing Director of Bharat Biotech, Krishna Ella said.
-
US Health Regulator Lifts Hold On Covaxin's Clinical Trials
The US Food and Drug Administration which has put on hold phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for jab in US, Canada
-
US Health Regulator Clears Covaxin For Clinical Trials In Adults In America
Bharat Biotech's COVID-19 vaccine Covaxin has been given clearance for clinical trials in adults by the US Food and Drug Administration (FDA).
-
Covaxin Maker Bharat Biotech's Nasal Booster Dose Trials Get Approval
Vaccine manufacturer Bharat Biotech has received approval to conduct Phase-III clinical trials of an intranasal booster dose on people who have received both doses of Covaxin.
-
Covaxin-Maker Says Booster Shot Over 90% Effective Against Omicron, Delta Variant
Bharat Biotech today said that trials have indicated that a booster shot of Covaxin neutralises the Delta and Omicron variants of Covid.
-
Data From Trials On 2-18-Year-Olds Very Encouraging: Covaxin Maker
Bharat Biotech today announced that Covaxin, its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III trials.
-
Covaxin Showed Good Response In Children During Trials: Covid Panel Chief
Covaxin has shown that it has a very good immune response in children in trials, Chairman of India's COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI) Dr NK Arora said on Sunday.
-
Centre's Decision To Vaccinate Children "Unscientific": Senior AIIMS Epidemiologist
A senior epidemiologist at AIIMS who is the principal investigator of Covaxin trials for adults and children at the institute on Sunday termed the Centre's decision to vaccinate children against Covid "unscientific".
-
Covaxin Meets WHO Criteria For Delta, Shows Lancet Study: Bharat Biotech
Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among the general population.
-
Bharat Biotech's US Partner Files Request With FDA For Covaxin Trials
Ocugen, Bharat Biotech's US partner for COVID-19 vaccine Covaxin, on Wednesday said it has submitted Investigational New Drug Application (IND) to the US Food and Drug Administration to conduct clinical trials.
-
Paediatric Covaxin: Bharat Biotech Completes Phase 2/3 Trials
Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman and Managing Director of Bharat Biotech, Krishna Ella said.
